science wire
« BACK
Pharmacology - Health - 03.12.2018
Health - Pharmacology - 03.12.2018
Health - Pharmacology - 02.12.2018
Health - Pharmacology - 01.12.2018
Health - Pharmacology - 01.12.2018
Health - Pharmacology - 30.11.2018
Pharmacology - Health - 29.11.2018
Pharmacology - Health - 29.11.2018
Health - Pharmacology - 28.11.2018
Health - Pharmacology - 27.11.2018
Health - Pharmacology - 23.11.2018
Health - Pharmacology - 23.11.2018
Innovation / Technology - Pharmacology - 23.11.2018
Health - Pharmacology - 22.11.2018
Health - Pharmacology - 21.11.2018
Physics - Pharmacology - 21.11.2018
Health - Pharmacology - 20.11.2018
Health - Pharmacology - 20.11.2018
Pharmacology - Health - 20.11.2018
Health - Pharmacology - 19.11.2018
Health - Pharmacology - 19.11.2018 
Fexinidazole - First All-Oral Treatment for Sleeping Sickness Approved
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness.
Health - Pharmacology - 19.11.2018
Health - Pharmacology - 16.11.2018
Health - Pharmacology - 16.11.2018
Pharmacology - Life Sciences - 16.11.2018 
Non-antibiotic drugs also speed up the spread of antibiotic resistance
New research from The University of Queensland has found non-antibiotic pharmaceuticals can significantly promote the spread of antibiotic resistance via bacterial mating.
Health - Pharmacology - 16.11.2018
Health - Pharmacology - 13.11.2018
Pharmacology - Health - 13.11.2018
Health - Pharmacology - 12.11.2018
Health - Pharmacology - 11.11.2018
Health - Pharmacology - 09.11.2018
Health - Pharmacology - 09.11.2018
Health - Pharmacology - 08.11.2018 
£438 million investment for UCL gene therapy spinouts
Prospective students Current students UCL spinout Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has raised $225 million (£173 million) through its initial public offering.
Pharmacology - Health - 05.11.2018
Health - Pharmacology - 05.11.2018
Pharmacology - Health - 02.11.2018
Pharmacology - Health - 02.11.2018
Life Sciences - Pharmacology - 01.11.2018
Pharmacology - Health - 01.11.2018
Pharmacology - Health - 01.11.2018
Pharmacology - Health - 01.11.2018
Pharmacology - Health - 31.10.2018
Pharmacology - Health - 29.10.2018
Pharmacology - Health - 27.10.2018
Pharmacology - Health - 26.10.2018
Health - Pharmacology - 24.10.2018
Pharmacology - Health - 23.10.2018
Pharmacology - Health - 22.10.2018
Health - Pharmacology - 22.10.2018
Health - Pharmacology - 21.10.2018
Pharmacology
Results 201 - 250 of 1314.
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoie
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoie
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
The AVXS-101, now known as ZOLGENSMA (onasemnogene abeparvovec-xxxx) , filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in achievement of developmental milestones compared to the natural history of SMA Type 1 SMA Type 1 is a progressive neuromuscular disease and the leading cause of genetic mortality in infants globally ZOLGENSMA represents the first in a propr
The AVXS-101, now known as ZOLGENSMA (onasemnogene abeparvovec-xxxx) , filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in achievement of developmental milestones compared to the natural history of SMA Type 1 SMA Type 1 is a progressive neuromuscular disease and the leading cause of genetic mortality in infants globally ZOLGENSMA represents the first in a propr
Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs.
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs.
Novartis announces longer-term analyses from pivotal Kymriah trials that showed durable responses are maintained in patients with advanced blood cancers
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion
Brexit clay and humanitarian solutions: News from the College
Here's a batch of fresh news and announcements from across Imperial. From a geological Brexit study captured in clay, to student solutions to global humanitarian aid challenges, here is some quick-read news from across the College.
Here's a batch of fresh news and announcements from across Imperial. From a geological Brexit study captured in clay, to student solutions to global humanitarian aid challenges, here is some quick-read news from across the College.
Disrupting Opioid Addiction
Students Aim To Create Preemptive Tool To ID High-risk Users Carnegie Mellon University students have created a new tool to help clinicians identify individuals with high-risk patterns of opioid use before it's too late.
Students Aim To Create Preemptive Tool To ID High-risk Users Carnegie Mellon University students have created a new tool to help clinicians identify individuals with high-risk patterns of opioid use before it's too late.
Novartis announces EU approval of Gilenya for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-f
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-f
Novartis announces landmark EU approval for one-time gene therapy Luxturna to restore vision in people with rare inherited retinal disease
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 g
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 g
Nutrients being trialled to manage OCD
University of Queensland researchers are conducting the Queensland trial of a new treatment for Obsessive-Compulsive Disorder (OCD) using an amino acid supplement.
University of Queensland researchers are conducting the Queensland trial of a new treatment for Obsessive-Compulsive Disorder (OCD) using an amino acid supplement.
Humpback whale songs simplified during ’cultural revolutions’
Humpback whales sing increasingly complex songs, but University of Queensland researchers have discovered they may suddenly switch to something simpler, in a ‘cultural revolution'.
Humpback whales sing increasingly complex songs, but University of Queensland researchers have discovered they may suddenly switch to something simpler, in a ‘cultural revolution'.
Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for intensive induction che
Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for intensive induction che
The Romeo and Juliet of particle physics comes to Lakeside
When Shakespeare and science collide - that's the essence of a new opera coming to Nottingham Lakeside Arts' Djanogly Theatre on University Park on Tuesday 27 November 2018.
When Shakespeare and science collide - that's the essence of a new opera coming to Nottingham Lakeside Arts' Djanogly Theatre on University Park on Tuesday 27 November 2018.
New immunotherapy improves MS symptoms
A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has improved symptoms and quality of life for the majority of patients. The treatment targets the Epstein-Barr virus (EBV), and is based on a theory formulated by University of Queensland and Royal Brisbane and Women's Hospital (RBWH) researcher Professor Michael Pender.
A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has improved symptoms and quality of life for the majority of patients. The treatment targets the Epstein-Barr virus (EBV), and is based on a theory formulated by University of Queensland and Royal Brisbane and Women's Hospital (RBWH) researcher Professor Michael Pender.
Sandoz and Pear Therapeutics announce launch of reSET for treatment of patients with Substance Use Disorder
ReSET is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of abus
ReSET is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of abus
Imaging project launched to transform treatment of kidney disease
A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.
A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness.
$2.5m to develop better skin treatments
Two projects to develop effective topical medicines have won almost $2.5 million ($US1.75) in US Food and Drug Administration grants.
Two projects to develop effective topical medicines have won almost $2.5 million ($US1.75) in US Food and Drug Administration grants.
FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval based on compelling benefit established through complete response rates among SAA patients when Promacta is added to standard immunosuppressive therapy relative to historic information on that therapy alone Promacta is the first new treatment in decades fo
Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval based on compelling benefit established through complete response rates among SAA patients when Promacta is added to standard immunosuppressive therapy relative to historic information on that therapy alone Promacta is the first new treatment in decades fo
Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs.
Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs.
New research from The University of Queensland has found non-antibiotic pharmaceuticals can significantly promote the spread of antibiotic resistance via bacterial mating.
New study aims to reduce the use of oral antibiotics for ear infections in children
Middle ear infections, known medically as acute otitis media (AOM), are common painful infections in children, for which there are up to three million treatment episodes in England and Wales each year.
Middle ear infections, known medically as acute otitis media (AOM), are common painful infections in children, for which there are up to three million treatment episodes in England and Wales each year.
Six things doctors would like you to know about antibiotics
Every day healthcare workers around the world are waging war, in what is becoming the fight of our lives.
Every day healthcare workers around the world are waging war, in what is becoming the fight of our lives.
FDA grants priority review to Roche’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Triple-negative breast cancer is an aggressive disease, with high unmet medical need If approved, this Tecentriq (atezolizumab) combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer Roche today announced the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq
Triple-negative breast cancer is an aggressive disease, with high unmet medical need If approved, this Tecentriq (atezolizumab) combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer Roche today announced the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq
Annual amnesty to tackle antibiotic resistance
Staff and students at Imperial are being encouraged to hand over their unused antibiotics as part of an annual amnesty.
Staff and students at Imperial are being encouraged to hand over their unused antibiotics as part of an annual amnesty.
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Entresto (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker fo
Entresto (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker fo
Federal authorities launch a campaign to promote appropriate use of antibiotics
Bern, 09.11.2018 - Maintaining the effectiveness of antibiotics for humans and animals, and combating resistance - these are the two main objectives of the national Strategy on Antibiot
Bern, 09.11.2018 - Maintaining the effectiveness of antibiotics for humans and animals, and combating resistance - these are the two main objectives of the national Strategy on Antibiot
Prospective students Current students UCL spinout Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has raised $225 million (£173 million) through its initial public offering.
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
26 potential blockbusters in confirmatory development. 13 projects in clinical development across Cell, Gene & Radioligand therapies.
26 potential blockbusters in confirmatory development. 13 projects in clinical development across Cell, Gene & Radioligand therapies.
Research will help to reduce limbo for cancer patients in the UK
A simple test to improve treatment for breast cancer patients invented by scientists in Nottingham could soon benefit people across the UK, as part of a £14 million national initiative.
A simple test to improve treatment for breast cancer patients invented by scientists in Nottingham could soon benefit people across the UK, as part of a £14 million national initiative.
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- a
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- a
Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Ten medicines featured in over 70 abstracts, including 25 oral presentations Additional data from three pivotal studies of Hemlibra in people with haemophilia A, with or without factor VIII inhibitor
Ten medicines featured in over 70 abstracts, including 25 oral presentations Additional data from three pivotal studies of Hemlibra in people with haemophilia A, with or without factor VIII inhibitor
Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil Data will be submitted to health authorities and prese
The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil Data will be submitted to health authorities and prese
Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Approval is based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by 83%
Approval is based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by 83%
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central sub
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central sub
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza First and only single-dose oral medicine approved to treat the flu Xofluza significantly reduced the duration of flu symptom
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza First and only single-dose oral medicine approved to treat the flu Xofluza significantly reduced the duration of flu symptom
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported significan
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported significan
Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot
Novartis COMBI-AD study of Tafinlar + Mekinist continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients
Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr